mRNA vs Therapeutic Vaccine — Oncology Deal Terms Comparison
Market Analysis
In oncology, mRNA and Therapeutic Vaccine represent two of the most actively transacted modalities. At Phase 2, mRNA deals carry a median total deal value of $2.1B with $335M upfront, compared to $1.9B total value and $297M upfront for Therapeutic Vaccine. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. mRNA development milestones average $448M versus $397M for Therapeutic Vaccine. Commercial milestones are $628M for mRNA and $555M for Therapeutic Vaccine. Royalty rates range from 12.8%-20.9% for mRNA and 12.3%-20.1% for Therapeutic Vaccine.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do mRNA and Therapeutic Vaccine deal terms compare in oncology?
Which modality commands higher royalty rates: mRNA or Therapeutic Vaccine?
How do milestone structures differ between mRNA and Therapeutic Vaccine?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.